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Introduction. An increasing number of women undergo breast augmentation procedures either for cosmetic reasons alone or
immediate reconstructions post-cancer surgery. Some studies suggest that irradiating a reconstructed/augmented breast may
result in an un-acceptable rate of cosmetic failure whereas others have found no detrimental effect.
Aims. Analyses were performed to determine tolerance and side effects of breast carcinoma patients with prosthetically aug-
mented or reconstructed breasts who had received radiotherapy (RT) at our institution.
Materials and methods. Between July and December 2012, 4 patients with prosthetically augmented or reconstructed breasts after
surgery (heterologous prosthesis) and 2 patients with expander treated with EBRT (50Gy/2Gy) were retrospectively reviewed.
They aged between 30 and 54 years old.
Results and discussion. It was observed that the expander has a density 12 and 40 times higher than breast and lung respectively,
so that there is a high gradient values. This implies more heterogeneity and higher ipsilateral lung irradiation. The conventional
prosthesis carriers showed low inﬂuence on the distribution of dose because they have similar density breast tissue. Due to these
differences the likelihood of dosimetric alterations is higher in this subgroup of patients, even though all cases met ICRU criteria.
In any case prosthesis carriers are relieved of other complications associated with skin or prosthesis disorders due to irradiation
(such as encapsulation). Our patients showed good tolerance to treatment, 3 had grade II radiodermatitis, and the 3 remaining
≤1. In no case encapsulation or implant removal was recorded.
Conclusions. Despite the fact that prosthesis carriers are prone to suffer more complications, our experience shows no major
differences from non-carriers, achieving oncological, cosmetic and dosimetric good outcomes.
http://dx.doi.org/10.1016/j.rpor.2013.03.117
Toxicity analysis of adjuvant radiotherapy in breast cancer
A. Otero Romero1, M. Espinosa Calvo1, M. Ariza2, C. Bueno Serrano1, P. Font Ugalde3, L. Tudela Beltrán1,
S. Garcia Cabezas1, M. López Díez1, A. Palacios Eito1
1 Hospital Reina Sofía, Servicio de Oncología Radioterápica, Spain
2 Hospital Reina Sofía, Servicio de Radiofísica y Protección Radiológica, Spain
3 Hospital Reina Sofía, Universidad de Córdoba, Spain
Introduction. Addition of radiotherapy to surgery has signiﬁcantly increased local control and survival rates in breast cancer.
In recent years new radiation schedules have been incorporated to our daily practice with a tendency to hypofractionation or
simultaneous integrated boost (SIB). Toxicity is frequently a concern when using these schemes.
Purpose. To identify factors related to toxicity in breast adjuvant radiotherapy.
Materials and methods. In 2011, 213 patients were treated with different schemes of adjuvant radiotherapy after breast conserving
surgery:whole breast + secuential boost, SIB, hypofractionation± secuential boost andonlywhole breast.We retrospectively com-
pare and analyse the relationship of acute toxicity with different variables: PTVvolume, PTVboost-volumen, radiation scheme,
total dose (TD), age, breast right/left, quadrant, grade, time of year, previous chemotherapy and hormone-therapy. ANOVA anal-
ysis was performed with quantitative variables and Kruskal–Wallis with qualitative variables. When differences were found
analysis with Mann–Whitney U was performed. SPPS programme V10.
Results. Median age 59 (30–83). Median PTVvolume 855.7 cm3 (178–2632). Skin acute toxicity G0 23.9%, G1 46.9%, G2 24.4% and G3
4.7%.No cardiac acute toxicitywas reported andonly 3patients presentedG1pulmonary acute toxicity and theywerenot included
in the statistical analysis. With a median follow-up of 15.7 months (2.5–27.5) 212 women are alive (99.5%). No differences were
found between toxicity and PTVboost-volumen, TD, age, breast right/left, quadrant, grade, time of year, previous chemotherapy
or hormone-therapy. We found differences with PTV volume, more grade of skin toxicity with higher volume of PTV (p=0.000).
We also found increased skin toxicity in relation to sequential boost scheme (p=0.005).
Conclusions. Hypofractionation or integration of the tumour bed boost shortens the overall treatment time compared to conven-
tional scheme, with an acceptable toxicity. We found statistically signiﬁcant differences of acute skin toxicity in relation to PTV
volume and sequential boost.
http://dx.doi.org/10.1016/j.rpor.2013.03.118
